Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunotherapy + Radiation in Resectable Soft Tissue Sarcoma
NCT03463408Phase 1Completed
- Sponsor
- University of Rochester
- Start
- Jul 2018
- Primary completion
- Aug 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of nivolumab and ipilimumab in soft tissue sarcoma (STS) (2 arms), sponsored by University of Rochester. Primary endpoint: Adverse Event evaluation at 2 years. Started Jul 2018; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT03463408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03463408.